<?xml version="1.0" encoding="UTF-8"?>
<ref id="R24">
 <label>24</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <string-name>
    <surname>Werth</surname>
    <given-names>V</given-names>
   </string-name>, 
   <string-name>
    <surname>Furie</surname>
    <given-names>R</given-names>
   </string-name>, 
   <string-name>
    <surname>Romero-Diaz</surname>
    <given-names>J</given-names>
   </string-name>
  </person-group>. 
  <article-title>OP0193 BIIB059, a humanized monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells (pDC), shows dose-related efficacy in the phase 2 LILAC study in patients (pts) with active cutaneous lupus erythematosus (CLE)</article-title>. 
  <source>Ann Rheum Dis</source>
  <year>2020</year>;
  <volume>79</volume>:
  <fpage>120</fpage>â€“
  <lpage>1</lpage>.
 </mixed-citation>
</ref>
